BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15474630)

  • 1. Predictors of adverse outcome from candidal infection in a tertiary care hospital.
    Ben-Abraham R; Keller N; Teodorovitch N; Barzilai A; Harel R; Barzilay Z; Paret G
    J Infect; 2004 Nov; 49(4):317-23. PubMed ID: 15474630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictors of outcome in immunocompetent patients with hematogenous candidiasis.
    Safdar A; Bannister TW; Safdar Z
    Int J Infect Dis; 2004 May; 8(3):180-6. PubMed ID: 15109594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-onset candidemia at a university hospital, 1995-2005.
    Kung HC; Wang JL; Chang SC; Wang JT; Sun HY; Hsueh PR; Chen YC
    J Microbiol Immunol Infect; 2007 Aug; 40(4):355-63. PubMed ID: 17712471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004.
    Al-Tawfiq JA
    Int J Infect Dis; 2007 May; 11(3):239-44. PubMed ID: 16859945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungemia in non-HIV-infected patients: a five-year review.
    Anunnatsiri S; Chetchotisakd P; Mootsikapun P
    Int J Infect Dis; 2009 Jan; 13(1):90-6. PubMed ID: 18653367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
    Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
    Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
    Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
    J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007.
    Nace HL; Horn D; Neofytos D
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):289-94. PubMed ID: 19376670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
    Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
    Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia.
    Uzun O; Ascioglu S; Anaissie EJ; Rex JH
    Clin Infect Dis; 2001 Jun; 32(12):1713-7. PubMed ID: 11360213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
    Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
    Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.
    Dimopoulos G; Ntziora F; Rachiotis G; Armaganidis A; Falagas ME
    Anesth Analg; 2008 Feb; 106(2):523-9, table of contents. PubMed ID: 18227310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
    Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
    Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the morbidity and pathogens of patients with candidemia at the intensive care unit].
    Yin QQ; Zhang YT; Fang Q
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 May; 29(5):464-8. PubMed ID: 18956679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
    Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
    Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
    Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
    Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata.
    Blot S; Vandewoude K; Hoste E; Poelaert J; Colardyn F
    J Hosp Infect; 2001 Apr; 47(4):308-13. PubMed ID: 11289775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.
    Davis SL; Vazquez JA; McKinnon PS
    Ann Pharmacother; 2007 Apr; 41(4):568-73. PubMed ID: 17374623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
    Chen TC; Chen YH; Tsai JJ; Peng CF; Lu PL; Chang K; Hsieh HC; Chen TP
    J Microbiol Immunol Infect; 2005 Jun; 38(3):200-10. PubMed ID: 15986071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.